相关实验视频
Updated: Apr 12, 2026

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.6K
早期发现 antracycline 的心脏毒性,并通过心力衰竭治疗改善
Daniela Cardinale1, Alessandro Colombo2, Giulia Bacchiani2
1From European Institute of Oncology, Milan, Italy (D.C., A.C., G.B., I.T., C.A.M., M.C., G.L., N.C., G.C., C.M.C.); and Centro Cardiologico Monzino (I.R.C.C.S.), Milan, Italy (F.V., C.F.). daniela.cardinale@ieo.it.
Circulation
|May 8, 2015
概括
人环素诱导的心脏毒性往往发生在治疗一年之内. 早期检测和心力衰竭治疗是恢复心脏功能的关键,特别是在较高的累积剂量下.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 人类循环素化疗可以引起心脏毒性,目前的分类缺乏强有力的支持数据.
- 需要进行前性评估,以了解 antracycline 诱导心脏毒性的发生率,时间和临床因素.
研究的目的:
- 为了前性地评估发生率,时间,临床相关性,和治疗反应的antracycline诱导心脏毒性.
- 调查影响心脏毒性发展和恢复的因素.
主要方法:
- 在2625名接受 antracyclines 治疗的患者中评估左心室喷射分数 (LVEF).
- 在化疗期间和之后监测LVEF,启动心力衰竭治疗心脏毒性.
- 从心脏毒性中定义和跟踪恢复.
主要成果:
- 整体心脏毒性发生率为9%,中位数发生在化疗后3.5个月;98%发生在第一年内.
- 在82%的受影响患者中,观察到心脏功能完全或部分恢复.
- 化疗结束后的LVEF和累积多克索鲁比剂量是心脏毒性的独立预测因素.
结论:
- 人环素诱导的心脏毒性主要表现在治疗后的第一年内.
- 心脏毒性与累积的环素剂量和治疗结束时的LVEF有关.
- 早期检测和及时的心力衰竭管理对于显著的心脏功能恢复至关重要.
相关概念视频
Cardiomyopathy II: Dilated Cardiomyopathy
801
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
801
Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
767
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
767
Heart Failure V: Medical Management
567
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567
Heart Failure VII: Nursing Interventions
743
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
743
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K

